Efficacy of aclidinium bromide in patients with stable COPD: Pooled analysis of phase III data by GOLD 2013 criteria
ConclusionsAclidinium improved lung function in all patients regardless of GOLD group; the numerically largest improvements were in Group A. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 23, 2014 Category: Respiratory Medicine Authors: Thomas, M., Price, D., Segarra, R., Garcia Gil, E. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study
CONCLUSIONS: Sustained improvements in lung function were observed in patients with COPD treated with a fixed-dose combination of aclidinium/formoterol for 1 year compared with formoterol. FDC tolerability was comparable to formoterol alone. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 23, 2014 Category: Respiratory Medicine Authors: Make, B., Donohue, J., Soong, W., Zhong, X., Leselbaum, A., Caracta, C. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies
ConclusionsAclidinium 400 µg BID may provide improvements in cough and sputum expectoration. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 23, 2014 Category: Respiratory Medicine Authors: McGarvey, L., Morice, A., Smith, J., Birring, S., Chuecos, F., Seoane, B., Jarreta, D. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on night-time and early morning symptoms in COPD
ConclusionsThese data suggest that aclidinium/formoterol FDC improves overall night-time and early morning symptom severity in patients with moderate to severe COPD compared with placebo and monotherapy. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 23, 2014 Category: Respiratory Medicine Authors: Singh, D., Chapman, K., Make, B., Mocarski, M., Serra, C., Garcia Gil, E. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Effects of aclidinium bromide/formoterol fumarate fixed-dose combination on health status in COPD
ConclusionThese studies indicate that aclidinium/formoterol FDC improves health status in patients with moderate to severe COPD, notwithstanding the large placebo effect that may have masked the treatment effect in ACLIFORM. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 23, 2014 Category: Respiratory Medicine Authors: Jones, P., Korn, S., Scanlon, P. D., Singh, D., Mergel, V., Molins, E., Leselbaum, A. Tags: 1.12 Clinical Problems - COPD Source Type: research
Interaction between aclidinium bromide and formoterol fumarate in small human airways
ConclusionsAclidinium and formoterol had a synergistic interaction on the lumen area enhancement of bronchioles, mainly at low concentrations. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 23, 2014 Category: Respiratory Medicine Authors: Cazzola, M., Calzetta, L., Page, C. P., Rogliani, P., Facciolo, F., Gavalda, A., Matera, M. G. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study
Background:
Aclidinium/formoterol is a twice-daily (BID) fixed-dose combination (FDC) in development for chronic obstructive pulmonary disease (COPD). The efficacy and safety of aclidinium/formoterol versus monotherapy and placebo in patients with COPD was assessed.
Methods:
In this 24-week double-blind, parallel-group, active- and placebo-controlled, multicentre Phase III study, patients (>=40 years, post-bronchodilator forced expiratory volume in 1 second [FEV1]/forced vital capacity =30% but (Source: BMC Pulmonary Medicine)
Source: BMC Pulmonary Medicine - November 18, 2014 Category: Respiratory Medicine Authors: Dave SinghPaul JonesEric BatemanStephanie KornCristina SerraEduard MolinsCynthia CaractaEsther GilAnne Leselbaum Source Type: research
The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide
This study characterised the in vitro and in vivo profiles of two novel long-acting muscarinic antagonists, aclidinium bromide and glycopyrronium bromide, using tiotropium bromide and ipratropium bromide as comparators. All four antagonists had high affinity for the five muscarinic receptor sub-types (M1–M5); aclidinium had comparable affinity to tiotropium but higher affinity than glycopyrronium and ipratropium for all receptors. Glycopyrronium dissociated faster from recombinant M3 receptors than aclidinium and tiotropium but more slowly than ipratropium; all four compounds dissociated more rapidly from M2 receptors ...
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research
Comparative Efficacy of Umeclidinium Bromide Versus Other Long-Acting Anticholinergic Monotherapies as Treatments for Copd Patients
To assess the relative efficacy of umeclidinium bromide 62.5 mcg OD (UMEC) versus tiotropium bromide 18 mcg OD (TIO), aclidinium bromide 400 mcg BID (AB) and glycopyrronium bromide 50 mcg OD (GLYCO). (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: A. Ismaila, E. Huisman, Y.S. Punekar Source Type: research
Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi.
Abstract
Long-acting muscarinic receptor antagonists (LAMAs) and long-acting β2-adrenoceptor agonists (LABAs) cause airway smooth muscle (ASM) relaxation via different signal transduction pathways, but there are limited data concerning the interaction between these two drug classes on human bronchi. The aim of this study was to investigate the potential synergistic interaction between aclidinium bromide and formoterol fumarate on the relaxation of human ASM. We evaluated the influence of aclidinium bromide and formoterol fumarate on the contractile response induced by acetylcholine or electrical field sti...
Source: European Journal of Pharmacology - October 22, 2014 Category: Drugs & Pharmacology Authors: Cazzola M, Calzetta L, Page CP, Rogliani P, Facciolo F, Gavaldà A, Matera MG Tags: Eur J Pharmacol Source Type: research
Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?
Abstract
Despite current guidelines and the range of available treatments, over a half of patients with asthma continue to suffer from poor symptomatic control and remain at risk of future worsening. Although a number of non-pharmacological measures are crucial for good clinical management of asthma, new therapeutic controller medications will have a role in the future management of the disease. Several long-acting anticholinergic bronchodilators are under investigation or are available for the treatment of respiratory diseases, including tiotropium bromide, aclidinium bromide, glycopyrronium bromide, glyc...
Source: Primary Care - July 19, 2014 Category: Primary Care Authors: Price D, Fromer L, Kaplan A, van der Molen T, Román-Rodríguez M Tags: NPJ Prim Care Respir Med Source Type: research
Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
CONCLUSION: Aclidinium bromide is an inhaled anticholinergic that improves lung function measures in patients with COPD. The most common adverse effects during clinical trials of the drug were headache, nasopharyngitis, and cough, none of which occurred at significantly higher rates than were seen with placebo use.
PMID: 24534593 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - February 22, 2014 Category: Drugs & Pharmacology Authors: Stone LE, Skelley JW, Kyle JA, Elmore LK Tags: Am J Health Syst Pharm Source Type: research
Effects of Aclidinium Bromide in a Cigarette Smoke-Exposed Guinea Pig Model of COPD.
Abstract
Long-acting muscarinic antagonists (LAMAs) are widely used to treat chronic obstructive pulmonary disease (COPD). In addition to bronchodilation, muscarinic antagonism may affect pulmonary histopathological changes. The effects of LAMAs have not been thoroughly evaluated in experimental models of COPD induced by chronic exposure to cigarette smoke (CS). We investigated the effects of aclidinium bromide on pulmonary function, airway remodeling, and lung inflammation in a CS-exposed model of COPD. 36 guinea pigs were exposed to CS and 22 sham-exposed, for 24 weeks. Animals were nebulized daily with ...
Source: Am J Respir Cell Mol... - September 13, 2013 Category: Respiratory Medicine Authors: Domínguez-Fandos D, Ferrer E, Puig-Pey R, Carreño C, Prats N, Aparici M, Musri MM, Gavaldà A, Peinado VI, Miralpeix M, Barberà JA Tags: Am J Respir Cell Mol Biol Source Type: research
Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD
Summary: Background: Aclidinium is a novel, long-acting muscarinic antagonist indicated for maintenance treatment of COPD.Methods: In this 52-week, parallel-group, double-blind study, patients with moderate-to-severe COPD were randomized (1:1) to receive aclidinium twice-daily (BID) 200 μg or 400 μg via a novel, dry powder inhaler (Genuair®/Pressair®) [Registered trademarks of Almirall, SA, Barcelona, Spain for use within the European Union, Iceland, Norway, and Switzerland as Genuair® and within the United States as Pressair®]. Safety, the primary objective, was assessed via adverse events (AEs), clinical laborato...
Source: Respiratory Medicine CME - August 2, 2013 Category: Respiratory Medicine Authors: Arthur F. Gelb, Donald P. Tashkin, Barry J. Make, Xiaoyun Zhong, Esther Garcia Gil, Cynthia Caracta, on behalf of the LAS-MD-35 study investigators Tags: COPD Source Type: research
Aclidinium Bromide: An Alternative Long-Acting Inhaled Anticholinergic in the Management of Chronic Obstructive Pulmonary Disease (July/August).
CONCLUSIONS:Aclidinium bromide is a novel, inhaled, long-acting anticholinergic that, when administered at the FDA-approved dose, safely produces clinically and statistically significant bronchodilation and improves health status in patients with moderate to severe COPD. Long-term clinical trials assessing the efficacy and safety of aclidinium are warranted.
PMID: 23737515 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - June 4, 2013 Category: Drugs & Pharmacology Authors: Woods JA, Nealy KL, Barrons RW Tags: Ann Pharmacother Source Type: research
